American Society of Clinical Oncology

SHERPA: White

People

  1. Norton
    Norton
  2. Hudis
    Hudis
  3. Dang
    Dang
  4. Troso-Sandoval
    Troso-Sandoval
  5. D'Andrea-Carlino
    D'Andrea-Carlino
  6. Fornier
    Fornier
  7. Lake
    Lake
  8. Sugarman
    Sugarman
  9. Drullinsky
    Drullinsky
  10. Seidman
    Seidman

Groups

  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (11)
  2. Breast Medicine Service (11)
  3. Department of Medicine (11)
  4. Gynecologic Medicine Service (11)
  5. Solid Tumor Oncology Division (11)
  6. GDMT, Medicine (10)
  7. Gynecology Disease Management Team (10)
  8. Survivorship Research (9)
  9. Epidemiology and Biostatistics (7)
  10. Biostatistics Service (6)
Search Within
  1. "Larry Norton"
  2. "Gynecologic Medicine Service"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (5)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (11)
  2. Breast Medicine Service (11)
  3. Department of Medicine (11)
  4. Gynecologic Medicine Service (11)
  5. Solid Tumor Oncology Division (11)
  6. GDMT, Medicine (10)

More Groups

People
  1. Larry Norton (11)
  2. Clifford Hudis (8)
  3. Chau Dang (6)
  4. Tiffany Troso-Sandoval (6)
  5. Diana Lake (5)
  6. Gabriella D'Andrea-Carlino (5)

More People

Years
  1. 2017 (1)
  2. 2015 (1)
  3. 2014 (2)
  4. 2009 (1)
  5. 2008 (2)
  6. 2006 (1)

More Years

Publications
  1. Journal of Clinical Oncology (11)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Meeting Abstract

    Smyth, L. M.; Iyengar, N. M.; Chandarlapaty, S.; Sugarman, S.; Comen, E. A.; Drullinsky, P.; Sklarin, N. T.; Traina, T. A.; Troso-Sandoval, T. A.; Patil, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer
    Meeting Abstract

    Drullinsky, P.; Fornier, M. N.; Sugarman, S.; D'Andrea, G.; Troso-Sandoval, T.; Seidman, A. D.; Yuan, J.; Patil, S.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study
    Journal Article

    Kauff, N. D.; Domchek, S. M.; Friebel, T. M.; Robson, M. E.; Lee, J.; Garber, J. E.; Isaacs, C.; Evans, D. G.; Lynch, H.; Eeles, R. A.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Norton, L.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers
    Journal Article

    Scheuer, L.; Kauff, N.; Robson, M.; Kelly, B.; Barakat, R.; Satagopan, J.; Ellis, N.; Hensley, M.; Boyd, J.; Borgen, P.; more...
    Journal of Clinical Oncology (2002)

    Fulltext@MSK | Save
  • Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer
    Journal Article

    Aghajanian, C.; Fennelly, D.; Shapiro, F.; Waltzman, R.; Almadrones, L.; O'Flaherty, C.; O'Conner, K.; Venkatraman, E.; Barakat, R.; Curtin, J.; more...
    Journal of Clinical Oncology (1998)

    Fulltext@MSK | Save